Pathogenesis and Natural History in a Longitudinal Hemangioma Syndrome Cohort

描述（由申请人提供）： 背景资料：PHACE综合征是面部大段血管瘤和先天性出生缺陷（如后颅窝畸形）的相关性。绝大多数病例是散发性的，表明从头或合子后体细胞突变可能是致病机制。差距：有一个根本缺乏知识的发病机制和自然史的发育异常，这种血管瘤综合征。目的：我们的主要目的是阐明这种血管瘤综合征的关键发育遗传途径。我们的第二个目标是将最严重的临床特征（主动脉缩窄、脑血管畸形和中风）与基因型相关联。目的：1）我们将使用下一代高通量测序技术，定制设计的分析管道和标准验证方法来鉴定PHACE中的镶嵌突变。2)我们将利用我们严格的临床PHACE表型登记和广泛的初步数据定义PHACE综合征的临床特征，以确定基因型-表型相关性。重要性：这项研究的贡献预计将是了解PHACE综合征的遗传基础以及与相关发育异常的表型相关性。这些知识将是重要的，因为它将推动预防战略，并为新的治疗药物提供关键目标。合作者：我们的多学科研究团队包括皮肤病学（Siegel，Drolet和Frieden），医学遗传学和儿童神经学（Dobyns），生物信息学（Worthey），基因组学（Worthey，Jacob和Shendure），统计学（霍夫曼）和细胞生物学（Rafiee）。

DESCRIPTION (provided by applicant): Background: PHACE syndrome is the association of large segmental facial hemangiomas and congenital birth defects, such as posterior fossa malformations. The vast majority of cases are sporadic, suggesting de novo or postzygotic somatic mutations may be the pathogenic mechanism. Gap: There is a fundamental lack of knowledge about the pathogenesis and natural history of the developmental anomalies in this hemangioma syndrome. Goal: Our primary objective is to elucidate the critical developmental genetic pathway involved in this hemangioma syndrome. Our secondary objective is to correlate the most severe clinical features (coarctation of the aorta, cerebrovascular anomalies and stroke) with the genotype. Aims: 1) We will use next generation high-throughput sequencing technology, custom designed analysis pipelines, and standard validation methods to identify mosaic mutations in PHACE. 2) We will capitalize on our rigorously phenotyped clinical PHACE registry and extensive preliminary data defining the clinical characteristics of PHACE syndrome to determine genotype-phenotype correlations. Significance: The contribution of the proposed research is expected to be an understanding of the genetic underpinnings of PHACE syndrome and phenotypic correlation with the associated developmental anomalies. This knowledge will be significant as it will drive strategies for prevention and provide critical targets for new therapeutic agents. Collaborators: Our multi-disciplinary study team includes expertise in dermatology (Siegel, Drolet and Frieden), medical genetics and child neurology (Dobyns), bioinformatics (Worthey), genomics (Worthey, Jacob and Shendure), statistics (Hoffman) and cell biology (Rafiee).